Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease.

Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review.

PMID:
17507545
2.

Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy.

de Boer WI, Alagappan VK, Sharma HS.

Cell Biochem Biophys. 2007;47(1):131-48. Review.

PMID:
17406066
3.

Treating COPD--the TORCH trial, P values, and the Dodo.

Rabe KF.

N Engl J Med. 2007 Feb 22;356(8):851-4. No abstract available. Erratum in: N Engl J Med. 2007 Apr 19;356(16):1692.

PMID:
17314345
4.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators.

N Engl J Med. 2007 Feb 22;356(8):775-89.

5.

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.

Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J; COPD Investigators.

Am J Respir Crit Care Med. 2007 May 1;175(9):926-34. Epub 2007 Feb 8.

PMID:
17290043
6.

Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.

Nénan S, Lagente V, Planquois JM, Hitier S, Berna P, Bertrand CP, Boichot E.

Eur J Pharmacol. 2007 Mar 15;559(1):75-81. Epub 2006 Dec 12.

PMID:
17234180
7.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.

Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, Rokosz LL, Kaiser B, Li G, Wang W, Stauffer T, Ozgur L, Baldwin J, Taveras AG.

J Med Chem. 2006 Dec 28;49(26):7603-6.

PMID:
17181143
8.

Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse.

Pemberton PA, Kobayashi D, Wilk BJ, Henstrand JM, Shapiro SD, Barr PJ.

COPD. 2006 Jun;3(2):101-8.

PMID:
17175673
9.

Mortality in COPD: Role of comorbidities.

Sin DD, Anthonisen NR, Soriano JB, Agusti AG.

Eur Respir J. 2006 Dec;28(6):1245-57. Review.

10.

Analysis of systemic biomarkers in COPD patients.

Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janciauskiene S.

COPD. 2004;1(2):155-64.

PMID:
17136983
11.

Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency.

Sampsonas F, Karkoulias K, Kaparianos A, Spiropoulos K.

Curr Med Chem. 2006;13(24):2857-73. Review.

PMID:
17073633
12.

Developing COPD: a 25 year follow up study of the general population.

Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J.

Thorax. 2006 Nov;61(11):935-9.

13.

CXCR2 blockade reduces radical formation in hyperoxia-exposed newborn rat lung.

Liao L, Ning Q, Li Y, Wang W, Wang A, Wei W, Liu X, Auten RL, Tanswell AK, Luo X.

Pediatr Res. 2006 Sep;60(3):299-303.

PMID:
16923948
14.

Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.

Pasternak A, Marino D, Vicario PP, Ayala JM, Cascierri MA, Parsons W, Mills SG, Maccoss M, Yang L.

J Med Chem. 2006 Aug 10;49(16):4801-4.

PMID:
16884289
15.

4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.

Butora G, Morriello GJ, Kothandaraman S, Guiadeen D, Pasternak A, Parsons WH, MacCoss M, Vicario PP, Cascieri MA, Yang L.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4715-22. Epub 2006 Jul 25.

PMID:
16870431
16.

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP.

Arthritis Rheum. 2006 Aug;54(8):2387-92.

17.

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT.

Am J Respir Crit Care Med. 2006 Oct 1;174(7):753-62. Epub 2006 Jul 13. Retraction in: Am J Respir Crit Care Med. 2011 Feb 1;183(3):418.

PMID:
16840747
18.

Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies.

Molfino NA, Jeffery PK.

Pulm Pharmacol Ther. 2007;20(5):462-72. Epub 2006 May 6. Review.

PMID:
16798034
19.

[Projections of future resource use and the costs of asthma and COPD in the Netherlands].

Hoogendoorn M, Feenstra TL, Rutten-van Mölken MP.

Ned Tijdschr Geneeskd. 2006 Jun 3;150(22):1243-50. Dutch.

PMID:
16796176
20.

Cytokines as targets in chronic obstructive pulmonary disease.

Chung KF.

Curr Drug Targets. 2006 Jun;7(6):675-81. Review.

PMID:
16787167

Supplemental Content

Support Center